• Progress made in all four drug development programs, including clinical-stage pipeline for PKD, RP11, ADOA, and pre-clinical stage pipeline for PMS
• Preparing for upcoming human safety and efficacy read-outs across all four programs in CY25, CY26, and CY27
• $135 million cash on hand with additional $20 million expected in Q1 2026

PYC Therapeutics, a precision medicine company, provided a quarterly update on the progress of its four drug development programs. In the third quarter of 2025, the company made progress in all four programs, including its clinical-stage pipeline for Polycystic Kidney Disease (PKD), Retinitis Pigmentosa type 11 (RP11), Autosomal Dominant Optic Atrophy (ADOA), and its pre-clinical stage pipeline for Phelan-McDermid Syndrome (PMS). The company is now preparing for upcoming human safety and efficacy read-outs across all four programs, with data expected in CY25 for the RP11 program, CY26 for the PKD and ADOA programs, and CY27 for the PMS program. As of September 30, 2025, the company had $135 million in cash on hand, with an additional $20 million expected to be received in Q1 2026 from an R&D rebate. The company's cash position supports the continued development of its drug candidates.